Stereotactic radiosurgery for melanoma brain metastases: dose-size response relationship in the era of immunotherapy

[1] Davies MA(2011)Prognostic factors for survival in melanoma patients with brain metastases Cancer 117 1687-1696

[2] Liu P(2016)Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery Cancer 122 3051-3058

[3] McIntyre S(2017)Peri-SRS administration of immune checkpoint therapy for melanoma metastatic to the brain: investigating efficacy and the effects of relative treatment timing on lesion response World Neurosurg 100 632-640.e634

[4] Qian JM(2015)Ipilimumab and Stereotactic Radiosurgery Versus Stereotactic Radiosurgery Alone for Newly Diagnosed Melanoma Brain Metastases Am J Clin Oncol 40 444-450

[5] Yu JB(2018)Immunotherapy and symptomatic radiation necrosis in patients with brain metastases treated with stereotactic radiation JAMA Oncol 4 1123-1124

[6] Kluger HM(2018)Focal radiation necrosis of the brain in patients with melanoma brain metastases treated with pembrolizumab Cancer Med 7 4870-4879

[7] Chiang VL(2000)Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90–05 Int J Radiat Oncol Biol Phys 47 291-298

[8] Yusuf MB(2016)Dose-volume response relationship for brain metastases treated with frameless single-fraction linear accelerator-based stereotactic radiosurgery Cureus 8 587-351

[9] Amsbaugh MJ(2017)A dose-volume response model for brain metastases treated with frameless single-fraction robotic radiosurgery: seeking to better predict response to treatment Technol Cancer Res Treat 16 344-506

[10] Burton E(2020)Radiosurgery dose reduction for brain metastases on immunotherapy (RADREMI): A prospective phase I study protocol Rep Pract Oncol Radiother 25 500-213

[1] Davies MA(2011)Prognostic factors for survival in melanoma patients with brain metastases Cancer 117 1687-1696

[2] Liu P(2016)Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery Cancer 122 3051-3058

[3] McIntyre S(2017)Peri-SRS administration of immune checkpoint therapy for melanoma metastatic to the brain: investigating efficacy and the effects of relative treatment timing on lesion response World Neurosurg 100 632-640.e634

[4] Qian JM(2015)Ipilimumab and Stereotactic Radiosurgery Versus Stereotactic Radiosurgery Alone for Newly Diagnosed Melanoma Brain Metastases Am J Clin Oncol 40 444-450

[5] Yu JB(2018)Immunotherapy and symptomatic radiation necrosis in patients with brain metastases treated with stereotactic radiation JAMA Oncol 4 1123-1124

[6] Kluger HM(2018)Focal radiation necrosis of the brain in patients with melanoma brain metastases treated with pembrolizumab Cancer Med 7 4870-4879

[7] Chiang VL(2000)Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90–05 Int J Radiat Oncol Biol Phys 47 291-298

[8] Yusuf MB(2016)Dose-volume response relationship for brain metastases treated with frameless single-fraction linear accelerator-based stereotactic radiosurgery Cureus 8 587-351

[9] Amsbaugh MJ(2017)A dose-volume response model for brain metastases treated with frameless single-fraction robotic radiosurgery: seeking to better predict response to treatment Technol Cancer Res Treat 16 344-506

[10] Burton E(2020)Radiosurgery dose reduction for brain metastases on immunotherapy (RADREMI): A prospective phase I study protocol Rep Pract Oncol Radiother 25 500-213